Skip to main content
SpringerLink
Log in

Breast cancer

  • Chapter
PET in Clinical Oncology

Abstract

The mammary gland is composed of glandular tissue within a dense fibroareolar stroma. The glandular tissue consists of approximately 15 to 20 lobes, each of which include a series of branching ducts and lobules. Most breast cancers arise in the terminal duct lobular unit. Histological classification is divided into invasive and non-invasive carcinomas and subdivided into ductal and lobular types. The most common types, representing about 80% of invasive breast cancers, are ductal carcinomas. Invasive lobular carcinomas account for approximately 10% and medullary carcinomas for 5% of malignant breast tumors. The remaining tumors comprise a variety of histological types that are generally less malignant. Rare tumors include the usually benign phylloides tumors and occasionally soft tissue sarcomas and primary lymphomas. Noninvasive breast cancer consists of two histological and clinical subtypes, ductal (DCIS) and lobular (LCIS) in situ carcinomas. The carcinoma cells are confined within the terminal duct lobular unit and the adjacent ducts, but have not yet invaded through the basement membrane. Traditionally, they were regarded as an early detectable stage of malignant transformation but LCIS is increasingly considered as a risk factor for developing invasive breast cancer. The breast acini are distended by fairly uniform carcinoma cells which grow into the duct system or break through the basement membrane to become invasive carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adler LP, Crowe JP, al-Kaisi NK, Sunshine JL (1993) Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology 187:743–750

    PubMed  CAS  Google Scholar 

  2. Adler LP, Faulhaber PF, Schnur KC, Al-Kasi NL, Shenk RR (1997) Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET. Radiology 203:323–327

    PubMed  CAS  Google Scholar 

  3. Avril N, Bense S, Ziegler SI, Dose J, Weber W, Laubenbacher C, Römer W, Jänicke F, Schwaiger M (1997) Breast imaging with fluorine-18-FDG PET: quantitative image analysis. J Nucl Med 38:1186–1191

    PubMed  CAS  Google Scholar 

  4. Avril N, Dose J, Jänicke F, Bense S, Ziegler S, Laubenbacher C, Römer W, Pache H, Herz M, Allgayer B, Nathrath W, Graeff H, Schwaiger M (1996) Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 14:1848–1857

    PubMed  CAS  Google Scholar 

  5. Avril N, Dose J, Jänicke F, Ziegler S, Römer W, Weber W, Herz M, Nathrath W, Graeff H, Schwaiger M (1996) Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)fluoro-2-deoxy-D-glucose. J Natl Cancer Inst 88:1204–1209

    Article  PubMed  CAS  Google Scholar 

  6. Avril N, Rose CA, Schelling M, Dose J, Kuhn W, Bense S, Weber W, Ziegler S, Graeff H, Schwaiger M (2000) Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. (submitted)

    Google Scholar 

  7. Avril N, Schelling M, Dose J, Weber W, Schwaiger M (1999) Utility of PET in breast cancer. Clin Pos Imag 2:261–271

    Article  Google Scholar 

  8. Bakheet SM, Powe J, Ezzat A, Al Suhaibani H, Tulbah A, Rostom A (1998) F-18 FDG whole-body positron emission tomography scan in primary breast sarcoma. Clin Nucl Med 23:604–608

    Article  PubMed  CAS  Google Scholar 

  9. Bassa P, Kim EE, Inoue T, Wong FC, Korkmaz M, Yang DJ, Wong WH, Hicks KW, Buz-dar AU, Podoloff DA (1996) Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 37:931–938

    PubMed  CAS  Google Scholar 

  10. Bender H, Kirst J, Palmedo H, Schomburg A, Wagner U, Ruhlmann J, Biersack HJ (1997) Value of 18 fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res 17:1687–1692

    PubMed  CAS  Google Scholar 

  11. Börner AR, Weckesser M, Herzog H, Schmitz T, Audretsch W, Nitz U, Bender HG, Müller-Gärtner HW (1999) Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med 26:226–230

    Article  Google Scholar 

  12. Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I (1998) Detection of bone metastases in breast cancer by F-18 FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 16:3375–3379

    PubMed  CAS  Google Scholar 

  13. Crippa F, Seregni E, Agresti R, Chiesa C, Pascali C, Bogni A, Decise D, De Sanctis V, Greco M, Daidone MG, Bombardieri E (1998) Association between F-18 fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med 25:1429–1434

    Article  PubMed  CAS  Google Scholar 

  14. Dehdashti F, Flanagan FL, Mortimer JE, Katzenellenbogen JA, Welch MJ, Siegel BA (1999) Positron emission tomographic assessment of “metabolic flare” to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 26:51–56

    Article  PubMed  CAS  Google Scholar 

  15. Dehdashti F, Mortimer JE, Siegel BA, Griffeth LK, Bonasera TJ, Fusselman MJ, Detert DD, Cutler PD, Katzenellenbogen JA, Welch MJ (1995) Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 36:1766–1774

    PubMed  CAS  Google Scholar 

  16. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB, Jr, Hoehn JL, Lees AW, Dimitrov NV, Bear HD (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672–2685

    PubMed  CAS  Google Scholar 

  17. Jansson T, Westlin JE, Ahlstrom H, Lilja A, Langstrom B, Bergh J (1995) Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 13:1470–1477

    PubMed  CAS  Google Scholar 

  18. Katzenellenbogen JA, Coleman RE, Hawkins RA, Krohn KA, Larson SM, Mendelsohn J, Osborne CK, Piwnica-Worms D, Reba RC, Siegel BA, Welch MJ, Shtern F (1995) Tumor receptor imaging: proceedings of the national cancer institute workshop, review of current work, and prospective for further investigations. Clin Cancer Res 1:921–932

    PubMed  CAS  Google Scholar 

  19. Kopans DB (1997) An overview of the breast cancer screening controversy. J Natl Cancer Inst Monogr 22:1–3

    PubMed  Google Scholar 

  20. Kubota K, Matsuzawa T, Amemiya A, Kondo M, Fujiwara T, Watanuki S, Ito M, Ido T (1989) Imaging of breast cancer with F-18 fluorodeoxyglucose and positron emission tomography. J Comput Assist Tomogr 13:1097–1098

    PubMed  CAS  Google Scholar 

  21. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicinbased neoadjuvant chemotherapy. J Clin Oncol 17:460–469

    PubMed  CAS  Google Scholar 

  22. McGuire AH, Dehdashti F, Siegel BA, Lyss AP, Brodack JW, Mathias CJ, Mintun MA, Katzenellenbogen JA, Welch MJ (1991) Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med 32:1526–1531

    PubMed  CAS  Google Scholar 

  23. Minn H, Soini I (1989) F-18 fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Am J Clin Pathol 91:535–541

    Google Scholar 

  24. Mintun MA, Welch MJ, Siegel BA, Mathias CJ, Brodack JW, McGuire AH, Katzenellenbogen JA (1988) Breast cancer: PET imaging of estrogen receptors. Br J Cancer 58:626–630

    Article  Google Scholar 

  25. Moon DH, Maddahi J, Silverman DH, Glaspy JA, Phelps ME, Hoh CK (1998) Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 39:431–435

    PubMed  CAS  Google Scholar 

  26. Palmedo H, Bender H, Grunwald F, Mallmann P, Zamora P, Krebs D, Biersack HJ (1997) Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumours. Eur J Nucl Med 24:1138–1145

    PubMed  CAS  Google Scholar 

  27. Parker SL, Tong T, Bolden S, Wingo PA (1996) Cancer statistics. CA Cancer J Clin 65:5–27

    Article  Google Scholar 

  28. Scheidhauer K, Scharl A, Pietrzyk U, Wagner R, Göhring UJ, Schomäcker K, Schicha H (1996) Qualitative F-18 FDG positron emission tomography in primary breast cancer: clinical relevance and practicability. Eur J Nucl Med 23:618–623

    Article  PubMed  CAS  Google Scholar 

  29. Schelling M, Avril N, Nährig J, Kuhn W, Römer W, Sattler D, Wener W, Dose J, Jänicke F, Graeff H, Schwaiger M (2000) Positron emission tomography using F-18 fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol (in press)

    Google Scholar 

  30. Torizuka T, Zasadny KR, Recker B, Wahl RL (1998) Untreated primary lung and breast cancers: correlation between F-18 FDG kinetic rate constants and findings of in vitro studies. Radiology 207:767–774

    PubMed  CAS  Google Scholar 

  31. Tse NY, Hoh CK, Hawkins RA, Zinner MJ, Dahlbom M, Choi Y, Maddahi J, Brunicardi FC, Phelps ME, Glaspy JA (1992) The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 216:2734

    Article  Google Scholar 

  32. UICC (1997) TNM. Classification of Malignant Tumors. Wiley-Liss, New York

    Google Scholar 

  33. Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M, Costa A, de Cicco C, Geraghty JG, Luini A, Sacchini V, Veronesi P (1997) Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 349:1864–1867

    Article  PubMed  CAS  Google Scholar 

  34. Wahl RL, Cody RL, Hutchins GD, Mudgett EE (1991) Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2- [F-18]-fluoro-2-deoxy-D-glucose. Radiology 179:765–770

    PubMed  CAS  Google Scholar 

  35. Wahl RL, Helvie MA, Chang AE, Andersson I (1994) Detection of breast cancer in women after augmentation mammoplasty using fluorine-18-fluorodeoxyglucose-PET. J Nucl Med 35:872–875

    PubMed  CAS  Google Scholar 

  36. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R (1993) Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 11:2101–2111

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. N. Avril
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Scheidhauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. Kuhn
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Bundeswehrzentralkrankenhaus Koblenz, Abteilung XV - Nuklearmedizin, Rübenacher Straße 170, Koblenz, 56072, Germany

    H. J. Wieler

  2. Division of Nuclear Medicine, Department of Radiology, DUMC 3949, Room 1419, Duke North Erwin Road, Durham, NC, 27710, USA

    R. Edward Coleman M.D. (Professor of Radiology, Vice-Chairman, Director) (Professor of Radiology, Vice-Chairman, Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Avril, N., Scheidhauer, K., Kuhn, W. (2000). Breast cancer. In: Wieler, H.J., Coleman, R.E. (eds) PET in Clinical Oncology. Steinkopff, Heidelberg. https://doi.org/10.1007/978-3-642-57703-1_28

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-57703-1_28

  • Publisher Name: Steinkopff, Heidelberg

  • Print ISBN: 978-3-642-63329-4

  • Online ISBN: 978-3-642-57703-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation